Tag Archives: Biotie Therapies Corp

Biotie Therapies Corp. announces change in the number of votes relating to its shares

TURKU, 16-3-2015 — /EuropaWire/ — Biotie Therapies Corp. (“Biotie” or the “Company”) has conveyed Biotie shares held as treasury shares, that were issued on 17 December 2014, pursuant to the Equity Incentive Plan 2011 (the “Plan”) as follows: Shares conveyed … Read the full press release

Biotie Therapies Corp: Clinical study with Biotie’s BTT1023 in primary sclerosing cholangitis awarded external grant funding

Turku, Finland, 25-7-2014 — /EuropaWire/ — Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with … Read the full press release

Biotie Therapies Corp. released its H1-2013 interim report

19-8-2013 — /EuropaWire/ — Company Highlights April – June 2013 Biotie obtained an exclusive option to acquire Neurelis, Inc., a private specialty pharmaceutical company based in San Diego, CA, focused on developing products for epilepsy and other disorders of the central nervous … Read the full press release

Biotie Therapies Corp. through its partner H.Lundbeck A/S introduced Selincro in the United Kingdom

Turku, 30-5-2013 — /europawire.eu/ — Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment … Read the full press release